摘要
[目的]探讨紫杉醇联合顺铂同步调强放疗治疗盆腔淋巴结阳性的Ⅲ期宫颈癌的临床疗效及不良反应。[方法]回顾性分析2013年4月至2016年4月我科收治90例Ⅲ期宫颈癌患者,其中44例采用紫杉醇联合顺铂方案同步放疗(联合组),46例患者接受顺铂单药周疗同步放疗(单药组)。[结果]紫杉醇联合顺铂组有效率为97.73%,顺铂单药组有效率为82.60%(P<0.05)。联合组和单药组患者3年PFS分别为29.55%(13/44)和4.35%(2/46)(P<0.05)。不良反应方面,联合组和单药组患者Ⅲ/Ⅳ°骨髓抑制发生率分别为38.64%和19.57%(P<0.05),Ⅲ°以上胃肠道反应分别为22.72%和43.48%(P<0.05),体重下降发生率分别为11.36%和28.26%(P<0.05);而血红蛋白下降、放射性膀胱炎和放射性直肠炎的发生率两组均无统计学差异(P>0.05)。[结论]紫杉醇联合顺铂同步放疗盆腔淋巴结阳性的Ⅲ期宫颈癌,疗效较好,放化疗的不良反应可以耐受。
[Objective] To evaluate the clinical efficacy and toxicities of concurrent intensity modulated radiotherapy(IMRT) with paclitaxel and cisplatin chemotherapy for stage Ⅲ cervical carcinoma patients with positive pelvic lymph nodes. [Methods] Ninety patients with stage Ⅲ cervical cancer treated with concurrent IMRT and chemotherapy from April 2013 to April 2016 were enrolled,including 44 patients received paclitaxel and cisplatin for chemotherapy(combination group) and 46 patients received cisplatin monotherapy(monotherapy group). [Results] The effective rate in the combination group was higher than that in monotherapy group(97.73% vs 82.60%,P<0.05). The 3 year-PFS of combination group was significantly higher than that of monotherapy group(29.55% vs 4.35%,P<0.05). The incidence of Ⅲ/Ⅳ degree myelosuppression was 38.64%in combination group and 19.57% in monotherapy group(P<0.05). The incidence of gastrointestinal reaction above Ⅲ degree of combination group and cisplatin group were 22.72% and 43.48%respectively(P<0.05),weight loss was 28.26% in monotherapy group and 11.36% in combination group(P<0.05). However,there was no difference in the incidence of reduced hemoglobin,radiation cystitis and radiation proctitis between two groups(P>0.05). [Conclusion] Combination of paclitaxel and cisplatin is effective and safe in concurrent radiochemotherapy for stage Ⅲ cervical cancer patients with positive pelvic lymph nodes.
作者
李承慧
龙婷婷
段爱雄
江启安
汪志求
LI Cheng-hui;LONG Ting-ting;DUAN Ai-xiong;JIANG Qi-an;WANG Zhi-qiu(Affiliated Anqing Hospital of Anhui Medical University,Anqing 246400,China)
出处
《肿瘤学杂志》
CAS
2019年第1期55-58,共4页
Journal of Chinese Oncology
关键词
宫颈癌
紫杉醇
调强放疗
疗效
cervical cancer
paclitaxel
IMRT
efficacy
